Eutilex Receives FDA Approval for 'EU101' Phase 1/2 Clinical Trial Plan

[Asia Economy Reporter Kum Boryeong] Eutilex announced on the 15th that it has received approval from the U.S. Food and Drug Administration (FDA) for the clinical phase 1/2 trial plan of the immuno-oncology drug 'EU101'.

The title of the clinical trial is "An open-label, phase 1/2 clinical trial to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of EU101, an anti-CD137 (4-1BB) agonist monoclonal antibody, in patients with advanced solid tumors."

The target disease (indication) is solid tumors. The clinical trial sites are two hospitals in the United States.

This content was produced with the assistance of AI translation services.